Genetic Risk Loci in Fibromyalgia Save

Know-it-now

• This GWAS provides the first robust genetic evidence that fibromyalgia is a biologically real, genetically linkied primarily CNS-driven disorder — heritability is confined to brain/neuronal tissue, with no immune or peripheral tissue enrichment.
• Top genetic hit is related to the genetics of Huntingtons disease -an HTT coding variant with a linked GPR52 signal, opens a genuine drug-repurposing pathway from Huntington's disease research.
• CELF4 identification gives direct genetic rationale for exploring gene-therapy approaches already in development for chronic pain.
• Genetic overlap with autoimmune disease (RA, Sjögren's) is real but weak; supporting fibromyalgia as distinct from classical autoimmune rheumatologic disease, relevant to ongoing diagnostic-overlap debates in clinic.

Researchers examined genetic data drawn from 11 different worldwide cohorts, that included from more than 2.5 million adults, of which 55,000 had been diagnosed with fibromyalgia. They identified DNA sequence variants in 26 regions of the genome that affect the risk of developing fibromyalgia. Many of the genes implicated in these regions are involved in brain and nerve function. This is the largest fibromyalgia GWAS to date. 

Top finding: an HTT coding variant. The strongest association (OR 1.09) was an inframe deletion in HTT, the Huntington's disease gene, located in the "A1" haplotype rather than the pathogenic CAG-repeat region; it did not track with the classic HD-causing variant. A second locus near GPR52 — an HTT regulator already an investigational HD drug target, offers the possibility of a genuine repurposing opportunity.

Broad neurodevelopmental and pain-signaling signal. Other prioritized genes include CAMKV (dendritic spine/synaptic plasticity), DCC (axon guidance, myelin structure), MDGA2 (synaptic organization; haploinsufficiency linked to autism), CELF4 (regulates nociceptor excitability — already a chronic-pain gene-therapy candidate), DRD2/NCAM1 (dopaminergic signaling and NK-cell marker CD56), and KYNU (kynurenine pathway, implicated in pain and depression).

Heritability maps exclusively to neural tissue. LDSC-SEG analysis found enrichment restricted to brain regions (cortex, caudate, putamen, anterior cingulate) and neuronal cell types — strongest in dentate gyrus neurons — with no enrichment in immune cells or peripheral tissues. This directly supports the central sensitization model over a peripheral/autoimmune one.

Autoimmunity: a weak, likely confounded signal. No MHC-region signal or immune cell-type enrichment was found. Genetic correlations with autoimmune disease were modest (rheumatoid arthritis r_g=0.33; Sjögren's r_g=0.39; psoriatic arthritis r_g=0.41) compared to pain/psychiatric traits, and fibromyalgia correlated more strongly with seronegative than seropositive RA and with T2-low (vs. T2-high) asthma — patterns the authors attribute partly to diagnostic misclassification in these less well-characterized disease subsets. The data argue against fibromyalgia being primarily autoimmune, while not excluding a minor immune component.

Extensive pleiotropy with comorbidities. Strongest genetic correlations were with widespread/syndromic pain conditions (cervicobrachial syndrome r_g=0.87, myalgia r_g=0.82, low back pain r_g=0.75) and PTSD (r_g=0.78), plus substantial overlap with IBS, depression, somatoform disorder, and insomnia — consistent with a shared, centrally-mediated vulnerability rather than coincidental co-occurrence.

Sex architecture is shared. Despite ~8:1 female predominance in cases, inter-sex genetic correlation was ~1.03 (indistinguishable from unity), and lead-variant effect sizes didn't differ by sex — implying prevalence differences stem from hormonal/environmental factors rather than sex-specific risk alleles.

A polygenic risk score showed modest but real stratification (AUC 0.59 in Europeans; prevalence 1.0% in lowest vs. 2.4% in highest quintile), with reduced portability to non-European ancestries given the predominantly European cohort.